February 10, 2010 - Oncologic Drugs Advisory Committee - http://FDAAC.com

To sign up for the live webcast, go to http://fdaac.com
FDAAdvisoryCommittee.com

February 10, 2010 - Oncologic Drugs Advisory Committee

NDA - PIXUVRI (Cell Therapeutics)

NDA - OMAPRO (ChemGenex Pharm)

Agenda: On February 10, 2010, during the morning session, the committee will discuss new drug application (NDA) 022-481, proposed trade name PIXUVRI (pixantrone dimaleate) injection, manufactured by Cell Therapeutics, Inc. The proposed indication (use) for this product is as a single agent treatment for patients with recurring or refractory (difficult to treat), aggressive non-Hodgkin’s lymphoma (NHL) who have received two or more prior lines of therapy.

During the afternoon session, the committee will discuss NDA 022-374, proposed trade name OMAPRO (omacetaxine mepesuccinate) for injection, manufactured by ChemGenex Pharmaceuticals. The proposed indication (use) for this product is for the treatment of adults with chronic myeloid leukemia (CML) bearing a genetic alteration known as the Bcr-Abl T315I mutation, and who have failed prior therapy with the drug imatinib.

Please Click HERE for our current calendar of upcoming events
To sign up for the live webcast, go to http://fdaac.com
FDAAdvisoryCommittee.com

REMINDER: FDA Social Media Webcast on November 12 & 13

November 12 & 13, 2009

Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet and Social Media Tools

To sign up for the live webcast, go to http://fdaac.com
FDAAdvisoryCommittee.com

Agenda: The Food and Drug Administration's (FDA's) Center for Drug Evaluation and Research (CDER), in collaboration with FDA's Center for Biologics Evaluation and Research (CBER), Center for Veterinary Medicine (CVM), and Center for Devices and Radiological Health (CDRH), is announcing a public hearing to discuss issues related to the promotion of FDAregulated medical products (including prescription drugs for humans and animals, prescription biologics, and medical devices) using the Internet and social media tools. FDA is seeking participation in the public hearing and written comments from all interested parties, including, but not limited to, consumers, patients, caregivers, health care professionals, patient groups, Internet vendors, advertising agencies, and the regulated industry. This meeting and the written comments are intended to help guide FDA in making policy decisions on the promotion of human and animal prescription drugs and biologics and medical devices using the Internet and social media tools. FDA is seeking input on a number of specific questions but is interested in any other pertinent information participants in the hearing would like to share.
To sign up for the live webcast, go to http://fdaac.com